Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
出版年份 2023 全文链接
标题
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
作者
关键词
-
出版物
LANCET
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2023-11-04
DOI
10.1016/s0140-6736(23)01613-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)
- (2023) Maria Carmela Piccirillo et al. Journal of Thoracic Oncology
- First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
- (2022) S. Peters et al. ANNALS OF ONCOLOGY
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
- (2022) Javier Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
- (2021) Paul Baas et al. LANCET
- Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity
- (2021) Luka Brcic et al. Cancers
- Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
- (2021) Nicoletta Colombo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
- (2021) Dean A Fennell et al. LANCET ONCOLOGY
- Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma
- (2020) Natasha K. Brockwell et al. Translational Lung Cancer Research
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- (2019) Arnaud Scherpereel et al. LANCET ONCOLOGY
- Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the Bio-MAPS cohort
- (2019) Solenn Brosseau et al. Clinical Lung Cancer
- Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)
- (2018) Samuel G. Armato et al. Journal of Thoracic Oncology
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Alternative metrics for assessing clinical benefit with immunotherapy in oncology
- (2017) E. Chan et al. OncoImmunology
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- The Worldwide Pandemic of Asbestos-Related Diseases
- (2013) Leslie Stayner et al. Annual Review of Public Health
- Multiple Testing in Group Sequential Trials Using Graphical Approaches
- (2013) Willi Maurer et al. Statistics in Biopharmaceutical Research
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started